Solutions

Online Inquiry

* Your Name

Phone Number

* E-mail Address

* Services Interested

Project Description

Please note that we are a research service provider, not a pharmacy or clinic, so we are unable to see patients and do not offer diagnostic and treatment services for individuals.

Phytotherapy Development Services

Phytotherapy encapsulates centuries of wisdom and now finds itself as a pioneer in integrative oncology, presenting promising bioactive compounds that influence key molecular mechanisms in the onset and advancement of cancer. A provider of phytotherapy development services, Protheragen uses our scientific knowledge and creative vision to exploit the healing powers of plants.

Overview of Phytotherapy

Phytotherapy is the use of plant parts for medicinal purposes, which utilizes active biological compounds from herbs, roots, leaves, barks, and resins. Flavonoids, alkaloids, terpenoids, and polyphenols are some of the bioactives with strong pharmacological activity. Phytochemicals act not like many conventional drugs, which work by only having one target action, as they have more complex mechanisms of action, such as modulatory actions of signaling pathways, alteration of gene expression, immune system regulation, and correction of metabolic dysregulation.

Mechanisms of action of natural products in cancer prevention.

Fig.1 Mechanisms of natural products in cancer prevention. (Jenča A., et al., 2024)

Phytotherapy Development in Cancer

Both empirical evidence and acceptance from authorities have propelled the phytotherapy sector in recent years. The global market for botanical drugs surpassed USD 110 billion in 2024, with nearly 20% of it coming from cancer-related applications.

However, challenges persist:

Lack of standardization in raw material sourcing and active compound quantification
Low bioavailability of many phytochemicals
Variable clinical efficacy without robust randomized controlled trials
Regulatory ambiguity in some jurisdictions regarding botanical classification

Table 1. Natural products (NPs) have demonstrated various mechanisms of action in exhibiting anticancer effects. (Jenča A., et al., 2024)

Mechanism of Action	Natural Product	Cancer Type(s)	Details
Inducing Apoptosis	Curcumin	Breast, colon, prostate, lung, glioblastoma	Regulates Bcl-2 family proteins, activates caspases, targets NF-κB, PI3K/Akt, MAPK pathways, enhances chemotherapeutic agents, and triggers intrinsic and extrinsic apoptotic pathways.
Inducing Apoptosis	Genistein	Breast, prostate, leukemia	Causes cell cycle arrest, alters cell cycle regulators, triggers caspase cascade, reduces anti-apoptotic proteins, inhibits NF-κB signaling, enhances chemotherapeutic sensitivity.
Inhibiting Cell Proliferation and Cell Cycle Progression	Ellagic acid	Breast, colon, melanoma, liver, ovarian, gastric, cervical	Induces G0/G1 arrest, modulates TGF-β1/Smad3 pathway, affects cyclin B1 and cdc2 kinase, and inhibits cell proliferation.
Inhibiting Cell Proliferation and Cell Cycle Progression	Quercetin	Breast, hepatocellular carcinoma	Causes G2/M phase arrest, modulates cyclin B1, cdc2, PI3K/Akt, MAPK, NF-κB pathways, and inhibits cell proliferation.
Interfering with Microtubule Formation	Vinca alkaloids	Hodgkin's lymphoma, non-Hodgkin's lymphoma, leukemia, non-small cell lung cancer, Kaposi sarcoma	Interfere with microtubule functions, inhibit cell division, bind to β-tubulin, and prevent polymerization.
Acting on Topoisomerase Targets and Preventing DNA Replication	Camptothecin	Breast, ovarian, lung, colorectal	Inhibits topoisomerase I, prevents DNA replication, induces apoptosis, and is used with other anticancer agents.
	Thymoquinone	Breast, lung, colon	Inhibits topoisomerase II, increases DNA cleavage.
Inhibiting Angiogenesis	Polyphenols	Skin, breast, lung, liver, colon, prostate, ovary	Target VEGF/VEGFR2, PI3K/Akt, MAPK, ERK, calcineurin/NFAT, HIF-1α pathways.
Inhibiting Angiogenesis	Polysaccharides	Esophagus, breast, lung, liver, colon, prostate, ovary	Display anti-angiogenic effects, alter tumor microenvironment, and modulate immune responses.
Modulating Key Signaling Pathways	Curcumin	Various cancers	Modulates NF-κB, PI3K/Akt, MAPK, JAK/STAT pathways, downregulates genes involved in cell proliferation, antiapoptosis, and metastasis.
Modulating Key Signaling Pathways	Resveratrol	Various cancers	Modulates SIRT1-dependent AMPK activation, suppresses STAT3 signaling, inhibits PI3K/Akt/mTOR pathway, and upregulates tumor suppressor miRNAs.
Improving the Tumor Microenvironment	Curcumin	Prostate	Reduces the invasive properties of cancer-associated fibroblasts by inhibiting mTOR/HIF-1α signaling, and accumulates in CAFs.
Improving the Tumor Microenvironment	Resveratrol	Gastric	Induces ER stress response, autophagy, apoptosis, and modulates immune cells and factors.
Reversing Multidrug Resistance	Flavonoids	Various cancers	Counteract MDR by inhibiting efflux proteins, inducing apoptosis, regulating the cell cycle, and modulating signaling pathways.
Reversing Multidrug Resistance	Alkaloids	Various cancers	Inhibit drug efflux transporters, modulate apoptosis pathways—examples: berberine, evodiamine, matrine.
Activating Immune Cells and Regulating Immune Function	Polyphenols	Various cancers	Modulate immune cells, inhibit immune checkpoints, induce immunogenic cell death, and deactivate key signaling pathways. Examples: curcumin, resveratrol.
Activating Immune Cells and Regulating Immune Function	Terpenoids	Various cancers	Enhance cancer immunotherapy by modulating immune cells, regulating immune function. Examples: paclitaxel, artemisinin.

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen is leading this revolution with its full-spectrum platform synthesizing raw botanicals into scientifically validated therapeutics. We strive to blend the wisdom of nature with biotechnology and develop targeted and effective phytotherapeutic solutions that are scalable and meet the stringent requirements of global pharmaceutical standards.

Target-Driven Compound Discovery

Protheragen uses a reverse pharmacology strategy starting from disease-target identification and mapping bioactive candidates via in silico predictions and high-throughput screenings. In silico predictions and high-throughput screenings of bioactive candidates are performed using our proprietary databases, which include more than 5000 traditional medicinal plant extracts and their derivatives.

Advanced Extraction and Characterization

We isolate the bioactive compounds with high specificity through pressurized liquid extraction, column chromatography, and bioassay-guided fractionation. Reproducibility and scalability for all plant materials are ensured by validated standard operating procedures (SOPs).

Preclinical Formulation Engineering

Most phytochemicals suffer from poor aqueous solubility. Our formulation team develops nanoparticle carriers, self-emulsifying drug delivery systems (SEDDS), and solid dispersions to optimize pharmacokinetics and maximize systemic exposure.

In Vitro and In Vivo Validation

We test candidates across diverse cancer cell lines (e.g., MCF-7, HepG2, A549), followed by xenograft and syngeneic mouse models for efficacy validation. All models follow standardized endpoints, including tumor volume inhibition, survival, and biomarker assessment.

The hallmark of Protheragen's phytotherapy development services lies in our ability to deliver precision, innovation, and customization. We offer tailored solutions to meet the specific needs of our clients, whether they are academic researchers, pharmaceutical companies, or herbal product manufacturers. If you are interested in our services, please feel free to contact us.

References

Jenča, Andrej, et al. "Herbal therapies for cancer treatment: A review of phytotherapeutic efficacy." Biologics: Targets and Therapy (2024): 229-255.
Zimmermann-Klemd, Amy M., et al. "Phytotherapy in integrative oncology—an update of promising treatment options." Molecules 27.10 (2022): 3209.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.